Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, de Braud F, Di Nicola M, Tagliabue E, Castagnoli L, Pupa SM.

Cell Oncol (Dordr). 2019 Aug 2. doi: 10.1007/s13402-019-00464-w. [Epub ahead of print]

PMID:
31376137
2.

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?

Castagnoli L, Ladomery M, Tagliabue E, Pupa SM.

Cancers (Basel). 2019 Jun 28;11(7). pii: E902. doi: 10.3390/cancers11070902. Review.

3.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L.

Sci Rep. 2019 Mar 5;9(1):3545. doi: 10.1038/s41598-019-40310-5.

4.

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Milani M, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM.

Oncogene. 2019 May;38(21):4047-4060. doi: 10.1038/s41388-019-0700-2. Epub 2019 Jan 31.

5.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
6.

Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.

Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, Di Nicola M, Morelli D, Tagliabue E, Pupa SM.

J Cell Physiol. 2019 Feb;234(2):1768-1779. doi: 10.1002/jcp.27049. Epub 2018 Aug 21.

7.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C.

Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.

8.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

9.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
10.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

11.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

12.

Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.

Pelosi G, Gasparini P, Conte D, Fabbri A, Perrone F, Tamborini E, Pupa SM, Ciravolo V, Caserini R, Rossi G, Cavazza A, Papotti M, Nakatani Y, Maisonneuve P, Pastorino U, Sozzi G.

J Thorac Oncol. 2016 May;11(5):718-728. doi: 10.1016/j.jtho.2016.01.009. Epub 2016 Jan 22.

13.

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavanè A, Cabras AD, Castagnoli L, Venerando B, Zaffaroni N, Gianni AM, De Braud F, Tripodo C, Pupa SM, Di Nicola M.

Blood. 2015 Mar 12;125(11):1768-71. doi: 10.1182/blood-2014-07-590034. Epub 2015 Jan 8.

PMID:
25573990
14.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

15.

Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).

Gabrielli F, Salvi R, Garulli C, Kalogris C, Arima S, Tardella L, Monaci P, Pupa SM, Tagliabue E, Montani M, Quaglino E, Stramucci L, Curcio C, Marchini C, Amici A.

PLoS One. 2013;8(3):e58358. doi: 10.1371/journal.pone.0058358. Epub 2013 Mar 28.

16.

Promise and failure of targeted therapy in breast cancer.

Giordano A, Tagliabue E, Pupa SM.

Front Biosci (Schol Ed). 2012 Jan 1;4:356-74. Review.

PMID:
22202065
17.

The HER2 World: Better Treatment Selection for Better Outcome.

Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S.

J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041.

PMID:
22043048
18.

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, Di Nicola M.

Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.

PMID:
21860023
19.

Activity and resistance of trastuzumab according to different clinical settings.

Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A.

Cancer Treat Rev. 2012 May;38(3):212-7. doi: 10.1016/j.ctrv.2011.06.002. Epub 2011 Jul 2. Review.

PMID:
21726959
20.

Do pre-diagnostic drinking habits influence breast cancer survival?

Allemani C, Berrino F, Krogh V, Sieri S, Pupa SM, Tagliabue E, Tagliabue G, Sant M.

Tumori. 2011 Mar-Apr;97(2):142-8. doi: 10.1700/667.7774.

PMID:
21617706
21.

The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.

Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, Tagliabue E, Pupa SM, Musiani P, Monaci P, Menard S, Amici A.

PLoS One. 2011 Apr 29;6(4):e18727. doi: 10.1371/journal.pone.0018727.

22.

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, Bottini A, Fantini M, Bonetti A, Pedani F, Mauri M, Molino A, Ferro A, Pupa SM, Sasso M, Ménard S, Balsari A, Tagliabue E.

Breast Cancer Res Treat. 2011 Jul;128(1):147-54. doi: 10.1007/s10549-011-1484-4. Epub 2011 Apr 11.

PMID:
21479926
23.

Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.

Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM.

J Cell Physiol. 2012 Feb;227(2):658-67. doi: 10.1002/jcp.22773.

PMID:
21465472
24.

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, Colombo MP, Carlo-Stella C, Gianni AM, Di Nicola M.

Cancer Res. 2010 Nov 15;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825. Epub 2010 Sep 30.

25.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359
26.

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM.

Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Review.

PMID:
20214497
27.

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM.

Blood. 2009 Jan 1;113(1):18-27. doi: 10.1182/blood-2008-06-165654. Epub 2008 Sep 22.

PMID:
18809757
28.

Regulation of breast cancer response to chemotherapy by fibulin-1.

Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E.

Cancer Res. 2007 May 1;67(9):4271-7.

29.

Role of exon-16-deleted HER2 in breast carcinomas.

Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S.

Endocr Relat Cancer. 2006 Mar;13(1):221-32.

PMID:
16601290
30.

SEL1L a multifaceted protein playing a role in tumor progression.

Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferrero S, Barberis M, Pupa SM, Scarpa A, Ménard S.

J Cell Physiol. 2006 Jul;208(1):23-38. Review.

PMID:
16331677
31.

Apoptosis induction by trastuzumab: possible role of the core biopsy intervention.

Ménard S, Pupa SM, Campiglio M, Balsari A, Fagnoni F, Costa A, Tagliabue E.

J Clin Oncol. 2005 Oct 1;23(28):7238-40. No abstract available. Erratum in: J Clin Oncol. 2006 Jan 20;24(3):531. Campiglio, Manuella [corrected to Campiglio, Manuela]; Taglibue, Elda [corrected to Tagliabue, Elda].

PMID:
16192615
32.

The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1.

Berno V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, Balsari A, Ménard S, Tagliabue E.

Endocr Relat Cancer. 2005 Jun;12(2):393-406.

PMID:
15947111
33.

A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.

Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA.

Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):351-63.

PMID:
15888257
34.

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

Pupa SM, Tagliabue E, Ménard S, Anichini A.

J Cell Physiol. 2005 Oct;205(1):10-8. Review.

PMID:
15887236
35.

Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.

Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S.

Cancer Res. 2005 Feb 1;65(3):1071-8.

36.

Role of HER2/neu in tumor progression and therapy.

Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E.

Cell Mol Life Sci. 2004 Dec;61(23):2965-78. Review.

PMID:
15583858
37.

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F.

Cancer Res. 2004 Apr 15;64(8):2858-64.

39.

Immunological and pathobiological roles of fibulin-1 in breast cancer.

Pupa SM, Argraves WS, Forti S, Casalini P, Berno V, Agresti R, Aiello P, Invernizzi A, Baldassari P, Twal WO, Mortarini R, Anichini A, Ménard S.

Oncogene. 2004 Mar 18;23(12):2153-60. Erratum in: Oncogene. 2004 Aug 19;23(37):6325. Argraves SW [corrected to Argraves WS].

PMID:
14691454
40.

Biologic and therapeutic role of HER2 in cancer.

Ménard S, Pupa SM, Campiglio M, Tagliabue E.

Oncogene. 2003 Sep 29;22(42):6570-8. Review.

PMID:
14528282
41.

Monoclonal antibody to fibulin-1 generated by genetic immunization.

Pupa SM, Forti S, Invernizzi AM, Giovanazzi R, Twal WO, Argraves WS, Ménard S.

J Cell Biochem. 2003 Jul 1;89(4):647-52.

PMID:
12858331
42.

Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Ménard S, Casalini P, Tagliabue E, Pupa SM, Balsari A.

J Natl Cancer Inst. 2003 Jun 18;95(12):917-8; author reply 918-9. No abstract available.

PMID:
12813176
43.

Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum.

Forti S, Scanlan MJ, Invernizzi A, Castiglioni F, Pupa S, Agresti R, Fontanelli R, Morelli D, Old LJ, Pupa SM, Ménard S.

Breast Cancer Res Treat. 2002 Jun;73(3):245-56.

PMID:
12160330
44.

New insights into the role of extracellular matrix during tumor onset and progression.

Pupa SM, Ménard S, Forti S, Tagliabue E.

J Cell Physiol. 2002 Sep;192(3):259-67. Review.

PMID:
12124771
45.

Humoral immune response for early diagnosis of breast carcinoma.

Pupa SM, Forti S, Balsari A, Ménard S.

Ann Oncol. 2002 Mar;13(3):483. No abstract available.

PMID:
11996483
46.

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL.

J Exp Med. 2001 Nov 5;194(9):1195-205.

47.

Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.

Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P, Lollini PL, Meazza R, Ferrini S, Menard S.

Gene Ther. 2001 Jan;8(1):75-9.

48.

p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma.

Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, Di Carlo E, Musiani P, Forni G, Menard S, Lollini PL.

Int J Cancer. 2000 Jul 15;87(2):186-94.

49.

Role of HER2 gene overexpression in breast carcinoma.

Ménard S, Tagliabue E, Campiglio M, Pupa SM.

J Cell Physiol. 2000 Feb;182(2):150-62. Review.

PMID:
10623878
50.

Supplemental Content

Support Center